BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, October 13 /PRNewswire-FirstCall/ -- Shire plc will announce third quarter 2006 US GAAP earnings on Friday, October 27, 2006.
Results announcement time: 12:00 BST / 07:00 ET Conference call time: 14:00 BST / 09:00 ET Live analyst conference call:
Matthew Emmens, Chief Executive Officer, Angus Russell, Chief Financial Officer and David Pendergast, President, Human Genetic Therapies will host the live analyst conference call at 14:00 BST/09:00 ET.
Please RSVP ssalah@uk.shire.com (T: +44(0)1256-894-160). The details of the live conference call are as follows: Canada Toll Free Dial In +1-800-795-6202 Number US Toll Free Dial In Number +1-866-224-2914 UK Toll Free Dial In Number +44(0)800-953-0937 Standard International Dial +44(0)1452-569-103 In Number Conference ID 8001751 Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the Investor Relations/Events section. A slide presentation to accompany the call will also be available in the same section.
Replay:
A replay of the presentation will be available for two weeks. Details are as follows:
UK Dial In Number +44(0)800-953-1533 USA Toll Free Number +1-866-247-4222 Std International Number +44-(0)-1452-55-00-00 Replay Access Number 8001751 # Webcast Replay www.shire.com, in the Investor Relations/Events section Notes to Editors SHIRE PLC
Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: www.shire.com.
Shire PLCCONTACT: For further information please contact: Investor Relations,Souheil Salah (Rest of the World), +44-1256-894-160, Heidi Wunder (NorthAmerica), +1-484-595-8709
